U.S. pharmaceutical industry is studied

Oct 12, 2006

A new study concludes the U.S. pharmaceutical industry might be wasting more than $50 billion every year in manufacturing expenses.

The finding is part of the largest empirical study ever performed of pharmaceutical manufacturing and the U.S. Food and Drug Administration's monitoring policies.

The study was conducted by Jackson Nickerson, professor of organization and strategy at Washington University in St. Louis, and Jeffrey Macher, assistant professor of strategy and economics at Georgetown University.

"We undertook the project to understand how the FDA regulates and pharmaceutical manufacturers produce, so we could see where there may be conflicts that inhibit advances in manufacturing," Nickerson said. "Our policy goal is to understand both sides of the coin so that we could contribute to improving the regulatory environment, thereby altering the pharmaceutical industry's incentives to maintain and in some cases enhance product quality but for a much lower cost."

The researchers collected data from 42 manufacturing facilities and determined companies extensively using information technology displayed superior manufacturing performance compared with other firms.

They also found the lower in the ranks a company allows employees to make decisions, the higher the company's overall manufacturing performance.

Copyright 2006 by United Press International

Explore further: New drug sales help boost Novartis Q1 profit (Update)

add to favorites email to friend print save as pdf

Related Stories

Rethink education to fuel bioeconomy, says report

Apr 15, 2014

Microbes can be highly efficient, versatile and sophisticated manufacturing tools, and have the potential to form the basis of a vibrant economic sector. In order to take full advantage of the opportunity microbial-based ...

Tracking catalytic reactions in microreactors

Feb 21, 2014

A pathway to more effective and efficient synthesis of pharmaceutical drugs and other flow reactor chemical products has been opened by a study in which for the first time the catalytic reactivity inside ...

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments : 0

More news stories

Genetic code of the deadly tsetse fly unraveled

Mining the genome of the disease-transmitting tsetse fly, researchers have revealed the genetic adaptions that allow it to have such unique biology and transmit disease to both humans and animals.